


Create Your Own Complimentary
MIGRAINE MANAGEMENT
Poster. Visit migrainemanagement.posterprogram.com



We'll ship it
to you directly
free of charge

THE CHANGING MIGRAINE MANAGEMENT LANDSCAPE: Can New and Emerging Therapeutic Options Benefit Your Patients?



To create your own poster, please visit
[HTTPS://MIGRAINEMANAGEMENT.POSTERPROGRAM.COM](https://migrainemanagement.posterprogram.com)

Migraine: Diagnosis and Management Resources

Resource	Address
Abu Bakar N, et al. Quality of life in primary headache disorders: A review. <i>Cephalalgia</i> . 2016;36(1):67-91.	https://pubmed.ncbi.nlm.nih.gov/25888584/
Ahmed F. Headache disorders: Differentiating and managing the common subtypes. <i>Br J Pain</i> . 2012;6(3):124-132.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590146/
Ailani J, et al. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. <i>Headache</i> . 2021;61(7):1021-1039.	https://pubmed.ncbi.nlm.nih.gov/34160823/
Ashina M, et al. Migraine: Epidemiology and systems of care. <i>Lancet</i> . 2021;397(10283):1485-1495.	https://pubmed.ncbi.nlm.nih.gov/33773613/
Ashina M, et al. Migraine: Integrated approaches to clinical management and emerging treatments. <i>Lancet</i> . 2021;397(10283):1505-1518.	https://pubmed.ncbi.nlm.nih.gov/33773612/
Berk T. Diagnosis and treatment of primary headache disorders in older adults. <i>J Am Geriatr Soc</i> . 2018;66(12):2408-2416.	https://pubmed.ncbi.nlm.nih.gov/30251385/
Bhakta M, et al. Migraine therapeutics differentially modulate the CGRP pathway. <i>Cephalalgia</i> . 2021;41(5):499-514.	https://pubmed.ncbi.nlm.nih.gov/33626922/
Burch R, et al. The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys. <i>Headache</i> . 2021;61(1):60-68.	https://pubmed.ncbi.nlm.nih.gov/33349955/
Burstein R, et al. Migraine: Multiple processes, complex pathophysiology. <i>J Neurosci</i> . 2015;35(17):6619-6629.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412887/
Caronna E, et al. Update on calcitonin ene-related peptide antagonism in the treatment of migraine. <i>Neurol Clin</i> . 2021;39(1):1-19.	https://pubmed.ncbi.nlm.nih.gov/33223077/

<p>Ceriani CEJ, et al. Novel medications for the treatment of migraine. <i>Headache</i>. 2019;59(9):1597-1608.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31559638/</p>
<p>Diener HC, et al. Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society. <i>Cephalalgia</i>. 2021;41(3):279-293.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/33472427/</p>
<p>Buse DC, et al. Life with migraine: Effects on relationships, career, and finances from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Headache</i>. 2019;59(8):1286-1299.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31407321/</p>
<p>Goadsby PJ. Primary headache disorders: Five new things. <i>Neurol Clin Pract</i>. 2019;9(3):233-240.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31341711/</p>
<p>Ha H, et al. Migraine headache prophylaxis. <i>Am Fam Physician</i>. 2019;99(1):17-24.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/30600979/</p>
<p>Kawata AK, et al. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of Tolerability and Effectiveness in Migraine Patients using Preventive Treatment (ATTAIN) study. <i>Headache</i>. 2021;61(3):438-454.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/33594686/</p>
<p>Masoud AT, et al. Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): A network meta-analysis of randomized controlled trials. <i>J Neurol Sci</i>. 2021;427:117505.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/34082147/</p>
<p>Negro A, et al. Gepants for the treatment of migraine. <i>Expert Opin Investig Drugs</i>. 2019;28(6):555-567.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31081399/</p>
<p>Peters GL, et al. Migraine overview and summary of current and emerging treatment options. <i>Am J Manag Care</i>. 2019;25(2 suppl):S23-S34.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/30681821/</p>
<p>Qubty W, et al. Migraine pathophysiology. <i>Pediatr Neurol</i>. 2020;107:1-6.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/32192818/</p>

Schoenen J, et al. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention. <i>Rev Neurol (Paris)</i> . 2020;176(10):788-803.	https://pubmed.ncbi.nlm.nih.gov/32758365/
Spindler BL, et al. Medications approved for preventing migraine headaches. <i>Am J Med</i> . 2020;133(6):664-667.	https://pubmed.ncbi.nlm.nih.gov/32145209/
Weatherall MW, et al. The diagnosis and treatment of chronic migraine. <i>Ther Adv Chronic Dis</i> . 2015;6(3):115-123.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416971/

Resources and Societies

Resource	Address
American Headache Society.	https://americanheadachesociety.org/
American Migraine Foundation.	https://americanmigrainefoundation.org/
International Headache Society Classification; ICHD-3.	https://ichd-3.org/
International Headache Society.	https://www.ihs-headache.org/
Migraine Research Foundation.	https://migraineresearchfoundation.org/
National Headache Foundation.	https://headaches.org/
National Institute of Neurological Disorders and Stroke, Headache Information Page. Last modified December 31, 2019.	https://www.ninds.nih.gov/Disorders/All-Disorders/Headache-Information-Page